Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 7/20 | 0.53 |
| ▸ | CA2 | P00918 | 7/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875446 | 0.98 | CAPN1 (0.61) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL3882611 | 0.98 | CAPN1 (0.61) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL3884455 | 0.98 | CAPN1 (0.61) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL13480197 | 0.87 | TDP1 (0.58) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL12418238 | 0.85 | TDP1 (0.65) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL1834665 | 0.84 | TDP1 (0.59) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL7207224 | 0.84 | TDP1 (0.69) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL15374970 | 0.84 | TDP1 (0.59) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL31108264 | 0.83 | CA1 (0.56) | CAPN1TDP1MEN1GAAKMT2A | |
| SCHEMBL10558245 | 0.83 | TDP1 (0.54) | CAPN1TDP1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124832-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | PROGEN PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124832-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | PROGEN PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7491849-B2 | Oligoamine compounds and derivatives thereof for cancer therapy | PROGEN PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491849-B2 | Oligoamine compounds and derivatives thereof for cancer therapy | PROGEN PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050080144-A1 | Oligoamine compounds and derivatives thereof for cancer therapy | PROGEN PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20030130356-A1 | Oligoamine compounds and derivatives thereof for cancer therapy | SLIL BIOMEDICAL CORPORATION | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080144-A1 | Oligoamine compounds and derivatives thereof for cancer therapy | THOP1, OAT, DUT | CAPN1 3206/4885TDP1 659/4885MEN1 1615/4885 |
| US-20090124832-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | THOP1, OAT, DUT | CAPN1 3206/4885TDP1 659/4885MEN1 1615/4885 |
| US-20030130356-A1 | Oligoamine compounds and derivatives thereof for cancer therapy | THOP1, OAT, DUT | CAPN1 3206/4885TDP1 659/4885MEN1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.